Nvidia’s Kimberly Powell is applying AI to expedite drug discovery

The molecular combinations involved in creating new treatments are vast, so Nvidia is customizing its technology to address the challenge.

Bringing a new drug to market usually requires a decade-long, multibillion-dollar journey, with a high failure rate in the clinical trial phase. Nvidia’s Kimberly Powell is at the center of a major industry effort to apply AI to the challenge.